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Abstract
Epidemiologic studies have established an association between exposures to air pollution particles
and human mortality and morbidity at concentrations of particles currently found in major
metropolitan areas. The adverse effects of pollution particles are most prominent in susceptible
subjects, including the elderly and patients with cardiopulmonary diseases. Controlled human
exposure studies have been used to confirm the causal relationship between pollution particle
exposure and adverse health effects. Earlier studies enrolled mostly young healthy subjects and
have largely confirmed the capability of particles to cause adverse health effects shown in
epidemiological studies. In the last few years, more studies involving susceptible populations have
been published. These recent studies in susceptible populations, however, have shown that the
adverse responses to particles appear diminished in these susceptible subjects compared to those
in healthy subjects. The present paper reviewed and compared control human exposure studies to
particles and sought to explain the "unexpected" response to particle exposure in these susceptible
populations and make recommendations for future studies. We found that the causes for the
discrepant results are likely multifactorial. Factors such as medications, the disease itself, genetic
susceptibility, subject selection bias that is intrinsic to many controlled exposure studies and
nonspecificity of study endpoints may explain part of the results. Future controlled exposure
studies should select endpoints that are more closely related to the pathogenesis of the disease and
reflect the severity of particle-induced health effects in the specific populations under investigation.
Future studies should also attempt to control for medications and genetic susceptibility. Using a
different study design, such as exposing subjects to filtered air and ambient levels of particles, and
assessing the improvement in biological endpoints during filtered air exposure, may allow the
inclusion of higher risk patients who are likely the main contributors to the increased particle-
induced health effects in epidemiological studies.
Introduction
Epidemiologic studies have established an association
between exposures to air pollution particles and human
mortality and morbidity at concentrations of particles cur-
rently found in major metropolitan areas [1]. This associ-
ation has been documented in numerous investigations
around the world and is remarkably consistent [1-8]. The
adverse effects of particulate matter (PM) include both
pulmonary and extrapulmonary morbidity and mortality.
It is estimated that the daily cardiopulmonary mortality
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increased by 0.3% for each 10-μg/m3 increase in PM10
(particulate matter < 10 μm in aerodynamic diameter).
For long term cardiopulmonary mortality, the estimate
was 6% for each 10-μg/m3 increase in annual average
exposure to PM2.5 (PM < 2.5 μm) [5]. The risk is especially
high in the elderly and patients with chronic obstructive
lung disease, asthma, coronary artery disease, congestive
heart failure and frequent arrhythmias [9-14]. The adverse
pulmonary effects after PM exposure include increased
hospital admissions, pulmonary infections, asthma
attacks, and exacerbations of chronic obstructive pulmo-
nary disease [10,15]. The extrapulmonary adverse effects
of PM are primarily cardiac diseases [1,5,16,17] and vas-
cular diseases (e.g., ischemic stroke) [18-21].
Controlled human exposures have been used to support
the association between PM exposure and adverse health
effects observed in epidemiological studies. Earlier con-
trolled human exposure studies invariably enrolled young
healthy subjects. These studies largely confirmed the capa-
bility for PM to produce adverse health effects shown in
epidemiological studies. In the last few years, more stud-
ies involving susceptible populations (e.g., elderly and
patients with coronary artery disease, chronic obstructive
lung disease and asthma) have been published [22-27]. It
is somewhat surprising that many studies showed that
these susceptible populations seem less responsive to PM
exposure compared to healthy individuals. This paper will
review all controlled exposure studies to PM in patients
with cardiopulmonary diseases and compare the health
effects of PM observed in these susceptible populations
with those in healthy subjects in human controlled in
exposure studies in an attempt to explain the seemingly
"paradoxical" response to PM in the susceptible popula-
tions. We will discuss factors that may affect the PM end-
points and provide recommendations for future studies
involving susceptible populations. Exposure studies that
employed only PM components, e.g., endotoxins or co-
pollutant gases, e.g. SO2, NO2 and CO, are beyond the
scope of this review and will not be included.
Controlled exposures to ambient pollutant particles
Controlled human exposure studies refer to those that
place study subjects in an exposure chamber into which
exogenous particles are introduced. Over the years, the
controlled human exposure studies have greatly enhanced
our understanding in PM-induced health effects, espe-
cially in apportioning the specific effects of particle con-
stituents and the mechanisms of the adverse effects. There
are, however, important limitations of controlled human
exposure studies.
Relative to animal and in vitro exposure studies, control-
led human exposures employ particles at concentrations
more relevant to the ambient level, but there are limita-
tions. Unlike animal and in vitro exposure studies, the
particle concentration to which the subject is exposed is
usually kept relative low for safety reasons. The duration
of the one-time exposure is usually short (1-2 hours). As
such, the biological effects may be small and the signal-
noise ratio can be unfavorable. Intermittent mild-to-
moderate exercise on a cycle ergometer is usually incorpo-
rated in the controlled exposure studies. Although this can
increase the dose of exposure, the interpretation of some
endpoints, e.g., HRV and DLCO, may be complicated by
the physiological effects induced by exercise itself. The
short one-time exposure makes it particularly difficult to
relate a negative result to "real world" exposure, which
most commonly is prolonged and repetitive. In addition,
the study endpoints for controlled human exposures are
limited to samples that are easily accessible, e.g., pulmo-
nary function, blood, sputum, ECG (for heart rate varia-
bility) and sometimes bronchoscopy specimens
(bronchoalveolar lavage fluid, bronchial brushing and
biopsy). It may be difficult to extrapolate changes in these
physiological and biochemical parameters to the end-
points frequently employed in epidemiological studies,
such as mortality, hospital admission and emergency
room visits.
Controlled human exposures may employ particles col-
lected on filters (and later given by nebulization), emis-
sion and crustal source particles, surrogate particles (e.g.,
carbon black) or ambient air pollution particles (with or
without concentration). The recovery of particles on filters
can be variable, and following such collection it is ques-
tionable whether all components can be retrieved in
quantities reflecting the original particles (e.g., organics
and ammonium are too volatile to be collected). In addi-
tion, the particles may be contaminated by fragments of
the filter when retrieved. Processed emission and crustal
source particles (e.g. residual oil fly ash, particles from
National Institute of Standards and Technology or NIST)
and artificially generated particles (e.g. carbon black),
while contributing to and included in ambient air pollu-
tion PM, are frequently deemed not truly representative of
such particles, and their use has equivalent or even greater
restrictions. The direct exposure of humans to ambient air
pollution (e.g. road tunnel air) has the advantage of using
relatively "fresh" particles, but it may be complicated by
factors that may not be easily controlled (e.g., fluctuating
levels of O3, SO2, and nitrogen oxides). Even in those
studies that artificially adjust the concentrations of these
co-pollutant gases to maintain a constant level of these
gases in the exposure chamber remained constant, interac-
tions between particles and co-pollutants cannot be
excluded. Ambient pollutant particles can also be concen-
trated before exposure of subjects [28]. Concentrated
ambient particles (CAPS) can be used to investigate the
specific effects of particles. CAPS are devoid of gaseous co-Environmental Health 2009, 8:33 http://www.ehjournal.net/content/8/1/33
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pollutants and possible interactions between PM and
these co-pollutants cannot be examined unless the latter
are re-introduced. CAPs exposures can also allow the
investigation of specific effects of particles within a size
range (e.g. PM2.5) by the use of a cascade impactor. Most
protocols include intermittent exercise on a stationary
bike during the exposure to elevate minute ventilation
and thus increase the dose of particles inhaled. Volunteers
are exposed sequentially or at random to filtered air and
pollutant(s) of interest, although the actual protocol used
varies in duration and timing. These variations in particle
sources and protocols can make it difficult to directly
compare results between controlled human exposure
studies.
Controlled exposures to ambient pollutant particles in 
patients with ischemic heart disease
Controlled exposure studies involving patients with cardi-
ovascular diseases that are discussed in this review are
summarized in Table 1. In a placebo controlled, double-
blinded, randomized, crossover study, Routledge et al.
[25] examined the effects of ultrafine carbon particles (at
50 μg/m3) as well as SO2 (200 ppb alone and in combina-
tion) on heart rate variability (HRV) and circulating mark-
ers of inflammation and coagulation. The control
exposure was bottled medical air. Twenty patients with
stable angina, multivessel coronary artery disease, and
good left ventricular function (with an ejection fraction of
40%) were recruited from the waiting list for coronary
artery bypass grafting. Medications were unchanged
through the study period. Twenty healthy volunteers of
similar ages served as the control. Subjects rested for 30
minutes before the baseline blood sample was drawn.
After an additional 15 minutes, two five-minute segments
of ECG, respiration, and arterial blood pressure data were
recorded during controlled respiration. Subjects were then
exposed to the pollutant for one hour. Blood samples and
two five-minute recordings of the HRV data were obtained
immediately after exposure and again at four hours.
Another blood sample was taken at 24 hours. Studies of
the remaining pollutants were repeated in random order
seven to 14 days apart with identical protocols. In healthy
subjects, exposure to ultrafine carbon particles resulted in
immediate small increases in RR interval, SDNN, and
rMSSD compared to air alone. Low frequency (LF) power
also increased. Although high frequency (HF) power rose
similarly, this did not reach statistical significance.
Changes in HRV measures were no longer significantly
different from those after air exposures four hours after
exposure. HRV did not change significantly immediately
after SO2 exposure, but RR interval, SDNN, rMSSD, and
PNN50 were significantly reduced at four hours post-
exposure, indicating a reduction in cardiac vagal control.
HF power also tended to decrease, but this did not reach
statistical significance. When exposures to carbon and SO2
were entered as factors in a repeated measure analysis of
variance, there was significant interaction between carbon
and SO2, such that the effect of SO2 on HRV appeared to
be modulated by the presence of carbon (p < 0.001 for
rMSSD and p < 0.005 for SDNN). Patients with stable
angina did not show any of the above changes in HRV.
There were no changes in the markers of hemostatic sys-
tem, including platelet aggregation, fibrinogen and D-
dimers in either healthy volunteers or patients with
angina.
Mills et al [24] exposed 20 men (mean age 60 years ± 1
year) with prior myocardial infarction to either dilute die-
sel exhaust (300 μg/m3 from idling Volvo TD45, 4.5 liters,
4 cylinders, 680 rpm diesel engine; median particle size
54 nm) or filtered air for one hour with exercise. The sub-
jects had had a myocardial infarction more than six
months prior to enrollment, had been treated with pri-
mary angioplasty and stenting, and were receiving stand-
ard secondary preventive therapy. In addition to unstable
coronary disease, men with angina pectoris, a history of
arrhythmia, diabetes mellitus, uncontrolled hyperten-
sion, renal failure, and hepatic failure were excluded. Cur-
rent smokers and men with asthma, significant
occupational exposures, or an intercurrent illness were
also excluded from the study. This was a double-blind,
randomized, crossover study. The two exposures were sep-
arated by at least two weeks. The average number of parti-
cles was 1.26 × 106/cm3. The average concentrations of
NOx, NO2, NO, CO and total hydrocarbon were 4.45 ±
0.02 ppm, 1.01 ± 0.01 ppm, 3.45 ± 0.03 ppm, 2.9 ± 0.1
ppm and 2.8 ± 0.1 ppm respectively. Endpoints included
vascular studies (requiring brachial artery cannulation
with a 27 gauge needle), plasma tissue plasminogen acti-
vator (tPA), plasminogen activator inhibitor-1 (PAI-1),
and C-reactive protein (CRP). Heart rate increase with
exercise was similar between diesel and filtered air. Myo-
cardial ischemia was detected during exercise in all sub-
jects. Relative to filtered air, there was a greater decrement
of ST segment during exposure to diesel exhaust and this
was interpreted as an increase in the exercise-induced
ischemic burden. Diesel exhaust did not aggravate preex-
isting vasomotor dysfunction measured as endothelium-
dependent (acetylcholine) and endothelium-independ-
ent (nitroprusside) vasodilatation at six hours after expo-
sure. Exposure to diesel exhaust did reduce the acute
bradykinin-induced release of endothelial tPA. There were
no differences in tPA, PAI-1, leukocyte and neutrophil
counts, platelet counts, and CRP.
These findings in patients with prior myocardial infarc-
tion [24] are in contrast to those observed in healthy sub-
jects published by the same group [29]. These authors
exposed 30 healthy men between 20 and 38 years old to
diluted diesel exhaust (300 μg/m3) or air for one hourEnvironmental Health 2009, 8:33 http://www.ehjournal.net/content/8/1/33
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using the same exposure protocol. This study of healthy
volunteers showed that diesel exhaust attenuated
increases in forearm blood flow induced by bradykinin,
acetylcholine, and nitroprusside infusion measured two
and six hours after exposure. Diesel exhaust also sup-
pressed the bradykinin-induced release in plasma tPA six
hours after exposure. Tornqvist et al [30] examined the
vascular dysfunction in 15 healthy volunteers 24 hours
after exposure to diesel exhaust or filtered air using the
same protocol as that of Mills et al. They also found that
exposure to diesel exhaust reduced acetylcholine- and
bradykinin-induced vasodilatation, but diesel exhaust
had no effects on endothelium-independent vasodilata-
tion induced by sodium nitroprusside or verapamil.
Unlike the studies by Mills et al [24,29], diesel exhaust did
not attenuate bradykinin-induced increase in plasma tPA.
Table 1: Controlled human exposure studies in patients with ischemic heart disease and metabolic syndrome.
Study Subject (number) Design Particles Results
Routledge et al [25] Healthy volunteers (20)
Patients with multivessel 
coronary disease (20)
Placebo controlled, 
double-blind, randomized
Filtered air
Carbon (50 μg/m3)
SO2 (200 ppb)
Carbon + SO2
Small increases in RR interval, SDNN, 
rMSSD LF power immediately post-
carbon exposure; Decreased RR 
interval, SDNN, rMSSD, and PNN50 at 
4 hours post-SO2 exposure
Mills et al [29] Healthy volunteers (30) Double-blind, 
randomized, crossover
Filtered air
Diesel exhaust (300 μg/
m3)
Attenuated forearm blood flow 
increase induced by bradykinin, 
acetylcholine, and nitroprusside 
infusion at 2 and 6 hours after 
exposure;
Suppressed the bradykinin-induced 
release in plasma t-PA 6 hours after 
exposure
Mills et al [24] Patients with prior 
myocardial infarction (20)
Double-blind, 
randomized, crossover
Filtered air
Diesel exhaust (300 μg/
m3)
Greater increase in the exercise-
induced ischemic burden and 
decrement of ST segment during 
exposure;
No effects on preexisting vasomotor 
dysfunction at 6 hours post-exposure;
Reduced the bradykinin-induced 
release of endothelial t-PA
Tornqvist et al [30] Healthy volunteers (15) Double-blind, 
randomized, crossover
Filtered air
Diesel exhaust (300 μg/
m3)
Decreased endothelium-dependent 
vasodilatation;
No effects on endothelium-
independent vasodilatation or the 
bradykinin-induced release of 
endothelial t-PA
Mills et al [31] Age-matched healthy 
volunteer (12)
Patients with stable 
coronary artery disease 
(12)
Double-blind, 
randomized, crossover
Filtered air
Fine and ultrafine CAPS 
(190 μg/m3)
CAPS did not affect vasomotor or 
fibrinolytic function in either middle-
aged healthy volunteers or patients 
with coronary heart disease.
Peretz et al [35] Healthy subjects (10)
Metabolic syndrome (17)
Double-blind, 
randomized, crossover
Filtered air
Diesel exhaust (100 and 
200 μg/m3)
Decreased brachial artery diameter, 
increased plasma ET-1; No differences 
between healthy subjects and patients 
with metabolic syndrome
Carlsten et al [36] Metabolic syndrome (16) Double-blind, 
randomized, crossover
Filtered air
Diesel exhaust (100 and 
200 μg/m3)
Decreased vWF at 7 hours 
postexposure
Carlsten et al [37] Healthy subjects (13) Double-blind, 
randomized, crossover
Filtered air
Diesel exhaust (100 and 
200 μg/m3)
No changes in prothrombotic 
endpointsEnvironmental Health 2009, 8:33 http://www.ehjournal.net/content/8/1/33
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Most recently, Mills et al conducted another study in
which 12 patients with stable coronary artery disease and
12 age-matched normal volunteers were exposed to con-
centrated ambient fine and ultrafine particles or filtered
air [31]. The mean particle concentration in the chamber
was 190 ± 37 μg/m3. They found an approximately three-
fold increase in exhaled breath 8-isoprostane after CAPs
exposure in both groups. CAPs exposure increased blood
flow and plasma tPA in a dose-dependent manner; how-
ever, there was no effect on vascular function in either
group. Because the ambient particles used in the study
were low in elemental carbon, the lack of changes in the
markers of vascular functions was attributed to the low
combustion-derived particles in CAPs. Of note, patients
with coronary artery disease also showed no increase in
exhaled breath 8-isoprostane, forearm blood flow and
plasma tPA compared to their age matched control [31].
Thus in patients with coronary artery disease, HRV effects
and endothelial dysfunction caused by diesel exhaust are
diminished or absent compare to those in healthy sub-
jects with no history of cardiovascular disease
[24,25,29,30]. Even if the exposure was to particles from
low combustion sources, patients with coronary artery
disease still show no increased responsiveness compared
to their age matched control [31]. These findings were
also in contrast to those from some panel studies. For
example, endothelial dependent and endothelial inde-
pendent vascular reactivity reduced only in patients with
diabetes [32]. Plasma plasminogen activator inhibitor-1
(PAI1) levels were significantly increased in a group of
patients with coronary artery disease when hourly concen-
trations of PM10 were greater than 100 μg/m3, although
the study did no include a control low risk group [33].
PM10 levels were associated positively with increased von
Willebrand factor (vWF) only in person with a history of
diabetes [34].
Controlled exposures to ambient pollutant particles in at-
risk patient populations
Controlled exposure studies involving at-risk populations
that are discussed in this review are summarized in Table
1. Peretz et al exposed 10 healthy subjects and 17 patients
with metabolic syndrome to filtered air (FA) and diesel
exhaust (DE) at two levels (100 μg/m3 and 200 μg/m3) for
two hours [35]. Before and after each exposure, they meas-
ured the brachial artery diameter (BAd) by B-mode ultra-
sound and collected blood samples for endothelin-1 (ET-
1) and catecholamines. They also assessed endothelium-
dependent flow-mediated dilation (FMD) postexposure.
Compared with FA, DE dose dependently decreased BAd.
DE at 200 μg/m3 increased plasma levels of ET-1. There
was no consistent impact of DE on plasma catecho-
lamines or FMD. Patients with metabolic syndrome and
healthy subjects had similar DE-induced changes.
Carlsten et al exposed 16 subjects with metabolic syn-
drome to filtered air and diesel exhaust (DE) at two levels
(100 μg/m3 and 200 μg/m3) for two hours [36], an expo-
sure protocol the same as that in the study by Peretz et al
[35]. They assessed several thrombotic biomarkers,
including D-dimer, von Willebrand factor (VWF), and
plasmin activator inhibitor-1 (PAI-1) at three, seven, and
22 h after exposure initiation. Except for a small decrease
in VWF at 7 h induced by DE at 200 μg/m3, there were no
changes in other primary endpoints at other time points.
A previous study on healthy subjects by Carlsten et al also
showed no changes in prothrombotic endpoints after DE
exposure [37].
Patients with metabolic syndrome are at risk for develop-
ing coronary heart disease. The lack of changes in this at-
risk population is in contrast to epidemiological studies
that showed increased vWF and hematological markers of
inflammation and impaired endothelial function in asso-
ciation with PM exposure [32,38,39].
Controlled exposures to ambient pollutant particles in 
patients with obstructive airway diseases
Controlled exposure studies involving patients with
obstructive airway diseases that are discussed in this
review are summarized in Table 2. Gong et al exposed 12
young healthy and 12 asthmatic volunteers (average FEV1
= 89%) to concentrated ambient particulates (CAPS) in
the fine (PM2.5) size range at an average concentration of
174 μg/m3, and to filtered air (FA) with intermittent exer-
cise [26]. Various respiratory and cardiovascular end-
points were measured. PM2.5  decreased systolic blood
pressure in asthmatics and increased in healthy subjects
relative to FA. There were no differences in the other end-
points, including spirometry, blood cell count, cells in
induced sputum, blood coagulability, systemic inflamma-
tion and HRV, between the healthy and asthmatic volun-
teers.
Frampton et al [40] and Pietropaoli et al [41] exposed 16
asthma patients with normal FEV1 to freshly generated
elemental ultrafine carbon particles (10 μg/m3) or filtered
air. Compared to healthy subjects exposed to the same
concentration of particles, there were no differences in air-
way inflammation parameters (including exhaled NO
and inflammatory cells in induced sputum). Ultrafine car-
bon particles exposure reduced expression of adhesion
molecules CD54 and CD18 on monocytes and CD18 and
CD49d on granulocytes, and increased lymphocyte
expression of activation marker CD25 in healthy subjects.
Ultrafine carbon particles exposure induced a different
leukocyte surface marker response in asthmatics with a
reduction in expression of CD11b on monocytes and
eosinophils and CD54 on granulocytes.Environmental Health 2009, 8:33 http://www.ehjournal.net/content/8/1/33
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Gong et al [22] exposed six elderly healthy subjects and 18
volunteers with COPD (mean FEV1 = 54%) on separate
days to (a) filtered air (FA); (b) 0.4 ppm NO2; (c) PM2.5
CAPS (~200 μg/m3); and (d) CAPS and NO2 together.
CAPS caused small decreases in maximal mid-expiratory
flow and arterial O2 saturation and the decrement was
greater in healthy than COPD subjects. Similarly, CAPS
produced a greater decrease in percentages of columnar
epithelial cells in sputum in the healthy subjects. In a sim-
ilar study by Gong et al [42], CAPS decreased ectopic beats
in COPD subjects relative to FA. Heart-rate variability over
multi-hour intervals was lower after CAP than after FA in
healthy elderly subjects but not in COPD patients.
Stenfors et al exposed 25 non-atopic subjects and 15
patients with mild asthma to two hours of diesel exhaust
(DE) (PM10, 108 μg/m3) or filtered air [43]. DE increased
airway resistance in both groups. During exposures, vol-
unteers alternately exercised on a bicycle ergometer and
rested for 15 min periods. Bronchoscopy with bronchial
biopsy was performed six hours after ceasing exposure.
Healthy subjects, but not asthmatics, had increased neu-
trophils, IL-8 and IL-6 in BAL fluid and P-selectin and
VCAM-1 in bronchial biopsy after DE exposure. Only
asthma patients had an increased in IL-10 after DE expo-
sure.
Table 2: Controlled human exposure studies in patients with obstructive airway diseases.
Study Subject (number) Design Particles Results
Gong et al [26] Healthy volunteers (12)
Patients with mild asthma 
(12)
Crossover Filtered air, Fine CAPS (174 
μg/m3)
CAPS induced modest and similar 
increases in parasympathetic 
stimulation of HRV in both groups
Gong et al [42] Healthy elderly, age (6)
Elderly patients with COPD 
(13)
Crossover Filtered air, Fine CAPS (200 
μg/m3)
Decrease in HRV in healthy 
elderly but not in COPD patients
Frampton et al [40] Healthy volunteers (40), 
Patients with asthma (16)
Crossover Filtered air
Ultrafine carbon particles 
(10, 25 and 50 μg/m3)
In healthy subjects, reduced CD54 
and CD18 on monocytes; 
decreased CD18 and CD49d on 
granulocytes; decreased CD25 in 
blood monocytes, basophils, and 
eosinophils; increased lymphocyte 
expression of CD25.
In asthma, reduced CD11b on 
monocytes and eosinophils, CD54 
on granulocytes, the percentage of 
CD4+ T cells, basophils, and 
eosinophils
Piatropaoli et al [41] Healthy volunteers (40), 
Patients with asthma (16)
Crossover Filtered air
Ultrafine carbon particles 
(10, 25 and 50 μg/m3)
No changes in airway eNO and 
total cell count/differentials in 
induced sputum; Increased 
percentage macrophages in the 
sputum of asthmatics;
No changes in IL-6 and IL-8 in the 
sputum
Gong et al [67] Healthy volunteers (4)
Patients with mild asthma 
(12)
Crossover Filtered air Coarse CAPS 
(157 μg/m3)
Decrease HR and PNN50 4 hours 
post-exposure
Stenfors et al [43] Healthy volunteers (25)
Patients with mild asthma 
(15)
Single-blind randomized 
crossover
Filtered air
Diesel exhaust (PM10, 108 
μg/m3)
Increased neutrophils, IL-8 and IL-
6 in BAL fluid and P-selectin and 
VCAM-1 in bronchial biopsy, no 
difference between normal and 
asthmatics
Gong et al [44] Healthy volunteers (14)
Patients with mild asthma 
(17)
Crossover Filtered air
Ultrafine CAPS (100 μg/m3 
or 145,000/cm3 particle 
counts
Decreased O2sat, FEV1 and low 
frequency power; no differences 
between normal and asthmaticsEnvironmental Health 2009, 8:33 http://www.ehjournal.net/content/8/1/33
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Gong et al [44] exposed adult volunteers (17 healthy, 14
asthmatic) in a controlled environmental chamber to fil-
tered air or concentrated ultrafine particles (UFP) col-
lected in a Los Angeles suburb with substantial motor
vehicle pollution. Exposures lasted two hours with inter-
mittent exercise. Inhaled particle counts (mean 145,000/
cm3, range 39,000-312,000) were typically 7-8 times
higher than ambient levels. Mass concentrations (mean
100 μg/m3, range 13-277) were not highly correlated with
counts. Relative to filtered air studies, UFP exposures were
associated with a 0.5% mean fall in arterial O2 saturation
estimated by pulse oximetry (p < 0.01), a 2% mean fall in
forced expired volume in one sec (FEV1) the morning
after exposure (p < 0.05), and a transient slight decrease in
low frequency (sympathetic) power in Holter recordings
during quiet rest (p < 0.05). Healthy and asthmatic sub-
jects were not significantly different across most end-
points.
Controlled exposure studies in patients with obstructive
airway diseases so far showed that patients with mild
asthma appear to have similar or decreased pulmonary
and systemic responses to PM exposure compared to
healthy volunteers. In addition, while elderly healthy sub-
jects showed changes in ventilatory function and HRV
after PM exposure, elderly patients with moderate COPD
are relatively unresponsive.
Factors responsible for the diminished responses in 
patients with cardiopulmonary diseases
The lack of increased pulmonary and systemic responsive-
ness to PM in patients with cardiopulmonary diseases
during controlled exposures are somewhat surprising
since epidemiological studies consistently show that these
patients have higher incidence of PM-associated morbid-
ity and mortality [1,3,14,16]. What may account for this
lack of increased pulmonary and systemic responsiveness
in these susceptible populations during controlled expo-
sure to PM?
The susceptible patients may have impaired baseline val-
ues and therefore have decreased response to PM. This
may apply to endpoints that have a maximal response,
such as blood flow, vasoconstriction and HRV. In the
study of Mills et al [24], the baseline forearm blood flow
was the same in patients with coronary heart disease com-
pared to matched healthy control. In the study by
Routledge et al [25], the HRV parameters were not differ-
ent between healthy volunteers and patients with coro-
nary artery disease. However, since few investigations
include head-to-head comparison between healthy and
diseased subjects in the same study, this remains a possi-
bility.
Medications may alter the response to PM exposure. The
subjects recruited into the controlled exposure studies are
often required to be on fully appropriate medications, a
condition that cannot be controlled in epidemiological
studies. In the study by Routledge et al. [25], 70% of the
patients were on β-blockers, 85% on aspirin and 90% on
statins. In the study by Mills et al. [24], all patients were
on aspirin, 90% on statins and 75% on a β-blocker. In the
studies by Gong et al. [22,42], all COPD patients were on
a stable regimen of bronchodilators and/or inhaled ster-
oids. Regularly prescribed β-blockers blunted the associa-
tion between air pollution and supraventricular
arrhythmias in a group of patients with an implanted car-
dioverter defibrillator [45]. Statins eliminated the associa-
tion between PM2.5 and decreased high frequency power
[46]. Not taking statins enhanced the associations
between PM2.5 and plasma VCAM-1 in patients with type
2 diabetes [39]. The association between personal PM10
exposures and blood pressure and brachial arterial flow
was only present in diabetic patients not taking vasoactive
medications [47]. Both β-blockers and bronchodilators
were found to attenuate PM-induced changes in SDNN
[48]. The medication effects appear not limited to expo-
sure to PM since the reduction in HRV markers of cardiac
vagal control observed in normal volunteers after expo-
sure to SO2 was not seen in patients with stable angina
[25].
Disease itself may modify the response to PM exposure.
Patients with COPD due to α 1-antitrypsin deficiency
demonstrated decreased cardiac parasympathetic modu-
lation and changes in these HRV indices positively corre-
lated with FEV1  [49]. Thus the baseline autonomic
nervous system dysfunction in COPD patients may mod-
ify their HRV response to PM exposure [49-51]. Patients
with obstructive airway diseases have different patterns of
deposition of PM during exposure. Studies examining par-
ticle deposition in the lung among patients with obstruc-
tive airway diseases showed that lung deposition fraction
increased in patients with various obstructive airway dis-
eases [52], but a greater proportion of the particles is
deposited in the proximal airways [53,54] resulting in a
decrease in effective surface area for particle-lung cell
interaction. The decrease in particle-cell interaction may
attenuate the biological effects of PM. The altered deposi-
tion pattern, however, may only explain part of the atten-
uated response in COPD patients. One previous study
showed that PM-induced increase in SDNN was more
prominent in COPD patients whose the baseline FEV1 was
smaller [48]. These factors may explain the inconsistent
associations between PM and various pulmonary and car-
diovascular endpoints in a panel study [55].
Subject selection bias may also have contributed to the
lack of increased responsiveness observed in controlledEnvironmental Health 2009, 8:33 http://www.ehjournal.net/content/8/1/33
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exposures of susceptible populations. Unlike epidemio-
logical studies that typically include a large cohort of
patients regardless of their risk profiles, all controlled
exposure PM studies involving susceptible populations
have very strict inclusion and exclusion criteria and thus
likely select the most stable patients, in part for safety rea-
sons. These patients tend to have optimal medications
and/or have received other disease-modifying interven-
tions, and thus are most "stable".
Patients selected for controlled exposure studies may carry
genetic traits that are protective and thus are inherently
less responsive than the usual susceptible patients. For
example, the PM2.5-associated decrease in high frequency
power was only detected in subjects without the GSTM1
allele, but not subjects with GSTM1 present [46]. Carriers
of C677T methylenetetrahydrofolate reductase (MTHFR)
genotypes (CT/TT) had lower SDNN than CC MTHFR
subjects [56]. Elderly subjects with the GSTM1 deletion
and the HMOX-1 long repeat had decreased SDNN, HF
and LF after PM2.5 exposure [57]. Subjects with two
hemochromatosis (HFE) gene polymorphisms (C282Y
and H63D) appear protected from the effect of particles
on cardiac autonomic function compared with wild-type
subjects [58].
Some susceptible population may have biologically up-
regulated counter-regulatory mechanisms that counter-
balance the decreased physiological reserve, or that actu-
ally mitigate air pollution exposures. Antioxidant systems
in the lung are induced in patients with COPD, and the
degree of induction may be sufficient to attenuate oxida-
tive stress induced by PM exposure [59-61].
Selection of study endpoints may also have some effects
on the results. Many of the endpoints used in controlled
exposure studies are not specific for the disease or condi-
tion that the subjects have. For example, HRV is a sensitive
measure for autonomic nervous system dysfunction but it
may be irrelevant if PM-induced health effects in patients
with asthma or COPD are mostly respiratory. The useful-
ness of a disease-specific endpoint that is related to PM-
induced health effects is best illustrated by the study of
Mills et al that showed increased ST depression during
exercise in patient with coronary artery disease [24] and
by the study of Stenfors et al that showed increased IL-10
in asthma patients after exposure to diesel exhaust [43].
Recommendations for future studies
To date, controlled PM exposure studies in patients with
chronic cardiopulmonary diseases have shown some
novel results. More controlled exposure studies enrolling
these patients are needed to better characterize the effects
and mechanisms by which PM causes cardiopulmonary
health effects in susceptible populations. Future studies
should include endpoints that are more specific to the
pathogenesis of the disease and measurements that are
most relevant to PM-induced adverse effects in the suscep-
tible population under investigation. Furthermore, all
studies should collect and store DNA samples so that
genetic polymorphism of each patient in controlled
human exposures can be obtained and correlated with the
endpoints if necessary. Finally, we may consider control-
led exposure using filtered air as the "intervention" rather
than the "control" conceptually. To this end, we are
reminded of a study that showed decreased leukocyte
count and IL-6 in the peripheral blood in a group of expe-
dition members who traveled from a more polluted Japa-
nese metropolitan to the Antarctica that has the
particulate number density <1% of that measured in
Japan [62]. One may consider a similar study design for
controlled exposure in which the susceptible subjects are
exposed to ambient levels of PM (with or without gaseous
co-pollutants) and filtered air and assess the improvement
in the biological endpoints. In this approach, filtered air
is considered as "intervention" and the ambient level of
PM is regarded as "control" conceptually. This approach
could decrease the potential risk of these susceptible sub-
jects from the exposure to high levels of PM and allow us
to include patients with more severe disease who are most
likely the populations that developed adverse effects with
exposure to PM. Although the improvement signal may
be small, they may be amplified in these higher risk
patients because they have much worse baseline values.
The same approach may also be used to study the most
vulnerable population, i.e., children. Exposing children to
CAPS in controlled exposure studies may generate signifi-
cant scrutiny and concerns because of the potential effects
of increased ambient PM on growth and development of
children [63-66].
Conclusion
Controlled exposure studies remain an integral part of the
research in PM-induced health effects. Controlled expo-
sure studies in normal volunteers in the past decades have
provided important insights and novel mechanisms for
the adverse health effects associated with ambient particle
exposure. More controlled exposure studies with novel
designs will be needed to better characterize the effects
and mechanisms by which PM causes cardiopulmonary
health effects in susceptible populations.
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